NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in December
Rhea-AI Summary
NewAmsterdam Pharma (Nasdaq: NAMS) announced that company management will participate in three investor conferences in early December 2025: the 8th Annual Evercore Healthcare Conference on Dec 2, 2025 (Ian Somaiya, CFO, fireside chat at 3:50 PM ET); Citi 2025 Global Healthcare Conference on Dec 3, 2025 (Michael Davidson, CEO, and Ian Somaiya, CFO, fireside chat at 3:15 PM ET); and the Piper Sandler 37th Annual Healthcare Conference on Dec 4, 2025 (Michael Davidson, CEO, and Ian Somaiya, CFO, fireside chat at 8:00 AM ET).
Live webcasts and archived replays of the fireside chats will be available via the company’s investor relations website at ir.newamsterdampharma.com.
Positive
- None.
Negative
- None.
NAARDEN, The Netherlands and MIAMI, Nov. 25, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that company management will participate in the following upcoming investor conferences:
- 8th Annual Evercore Healthcare Conference in Coral Gables, FL on Tuesday, December 2, 2025. Ian Somaiya, Chief Financial Officer, will participate in a fireside chat at 3:50 p.m. ET on Tuesday, December 2.
- Citi’s 2025 Global Healthcare Conference in Miami, FL on Wednesday, December 3, 2025. Michael Davidson, M.D., Chief Executive Officer, and Ian Somaiya, Chief Financial Officer, will participate in a fireside chat at 3:15 p.m. ET on Wednesday, December 3.
- Piper Sandler 37th Annual Healthcare Conference in New York, NY on Thursday, December 4, 2025. Michael Davidson, M.D., Chief Executive Officer, and Ian Somaiya, Chief Financial Officer, will participate in a fireside chat at 8:00 a.m. ET on Thursday, December 4.
Live webcasts of the fireside chats will be available through the investor relations section of the NewAmsterdam Pharma website at ir.newamsterdampharma.com. Following the live webcasts, archived replays will be available on the Company’s website.
About NewAmsterdam
NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple phase 3 trials, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated.
Company Contact
Matthew Philippe
P: 1-917-882-7512
matthew.philippe@newamsterdampharma.com
Media Contact
Real Chemistry on behalf of NewAmsterdam
Christian Edgington
P: 1-513-310-6410
cedgington@realchemistry.com
Investor Contact
Precision AQ on behalf of NewAmsterdam
Austin Murtagh
P: 1-212-698-8696
austin.murtagh@precisionaq.com
FAQ
When will NewAmsterdam Pharma (NAMS) present at the Evercore Healthcare Conference?
Who from NewAmsterdam Pharma will appear at Citi’s Global Healthcare Conference on December 3, 2025?
What time is NewAmsterdam Pharma’s Piper Sandler fireside chat on December 4, 2025?
Where can investors watch NewAmsterdam Pharma’s conference presentations live?
Will archived replays of NewAmsterdam Pharma’s conference presentations be available after the events?
What is NewAmsterdam Pharma’s Nasdaq ticker and focus mentioned for these December 2025 conferences?
